In a Phase III trial, delamanid drug was found to be safe but the cure rate and mortality rate were not different between the group that received the delamanid drug for MDR-TB and the group that received a placebo. The culture conversion rate too did not show statistically significant difference at two or six months. … Continue reading WHO revises advice on use of delamanid drug in MDR-TB patients
Delamanid
India wants to eliminate TB by 2025 but falters on several critical fronts
In 2015, India accounted for nearly 2.8 million (27%) of the 10.4 million new tuberculosis (TB) cases in the world, and 0.48 million (29%) of the 1.8 million TB deaths globally. Yet, India brings up the rear on most critical fronts to fight the disease. This has been clearly highlighted by the ‘Out of Step’ … Continue reading India wants to eliminate TB by 2025 but falters on several critical fronts
Science Chronicle 